Genmab A/S Dkk (GNMSF) 40.7500 $GNMSF
Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration
GlobeNewswire - Wed Sep 10, 7:15AM CDT
Company Announcement
Major Shareholder Announcement
GlobeNewswire - Mon Aug 25, 11:08AM CDT
Company Announcement
Genmab Announces Financial Results for the First Half of 2014 and Improves 2014 Financial Guidance
GlobeNewswire - Wed Aug 13, 10:10AM CDT
Interim Report First Half 2014
Genmab Announces New Phase III Study of Daratumumab in Front Line Multiple Myeloma
GlobeNewswire - Mon Aug 11, 9:00AM CDT
Company Announcement
GSK and Genmab Announce Positive Interim Result for Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLL
GlobeNewswire - Thu Jul 31, 1:50PM CDT
Company Announcement
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
Second Quarter 2014 Net Sales Figures for Arzerra(r)
GlobeNewswire - Wed Jul 23, 6:11AM CDT
Company Announcement
Genmab Announces Phase III Study of Daratumumab in Front Line Multiple Myeloma
GlobeNewswire - Fri Jul 18, 8:18AM CDT
-- New Phase III study of daratumumab in front line multiple myeloma
Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer
Genmab to Receive Milestone Payment in DuoBody Platform Collaboration with Janssen
GlobeNewswire - Mon Jul 14, 8:59AM CDT
Genmab A/S (OMX:GEN) announced today it has reached a milestone in its DuoBody technology platform collaboration with Janssen Biotech, Inc. ("Janssen"
, triggering a $3 million milestone payment. The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting two inflammatory mediators, proteins which play a key role in major autoimmune diseases.
Johnson & Johnson to Make $25M Milestone Payment to Genmab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 12:10PM CDT
The payment was triggered by progress in an ongoing phase III study on experimental cancer treatment, daratumumab.
Genmab Reaches USD 25 Million Milestone in Daratumumab Collaboration with Janssen
GlobeNewswire - Mon Jul 07, 9:24AM CDT
Company Announcement
GSK and Genmab Receive EU Authorization for Arzerra(tm) (ofatumumab) as First-Line Treatment for Chronic Lymphocytic Leukemia (CLL) in Combination with Chlorambucil or Bendamustine for Patients Ineligible for Fludarabine-based Therapy
GlobeNewswire - Thu Jul 03, 8:39AM CDT
Company Announcement
GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians' choice for bulky fludarabine-refractory CLL
GlobeNewswire - Fri Jun 27, 1:27PM CDT
Company Announcement
Genmab Reaches $22 Million Milestone in Daratumumab Collaboration with Janssen
GlobeNewswire - Wed Mar 26, 5:58PM CDT
Company Announcement
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Tue Mar 04, 11:48PM CST
Company Announcement
Genmab 2013 Annual Report
GlobeNewswire - Tue Mar 04, 10:23AM CST
Genmab A/S (Copenhagen:GEN) today published its Annual Report for 2013. Below is a summary from the report of business progress and financial performance for the year, and financial outlook for 2014. The full report is attached as a PDF file and can be found on the investor section of the company's website, www.genmab.com.
Arzerra(R) Fourth Quarter and Full Year 2013 Net Sales Figures
GlobeNewswire - Wed Feb 05, 6:15AM CST
Company Announcement
Can Genmab (GNMSF) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 7:47AM CST
Genmab could be an interesting play for investors because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
Seattle Genetics and Genmab Enter Into New Antibody-Drug Conjugate Collaboration
GlobeNewswire - Wed Sep 10, 7:15AM CDT
Company Announcement
Major Shareholder Announcement
GlobeNewswire - Mon Aug 25, 11:08AM CDT
Company Announcement
Genmab Announces Financial Results for the First Half of 2014 and Improves 2014 Financial Guidance
GlobeNewswire - Wed Aug 13, 10:10AM CDT
Interim Report First Half 2014
Genmab Announces New Phase III Study of Daratumumab in Front Line Multiple Myeloma
GlobeNewswire - Mon Aug 11, 9:00AM CDT
Company Announcement
GSK and Genmab Announce Positive Interim Result for Phase III Study of Ofatumumab as Maintenance Therapy for Relapsed CLL
GlobeNewswire - Thu Jul 31, 1:50PM CDT
Company Announcement
Global Rheumatoid Arthritis Drugs Market 2014-2018
M2 - Mon Jul 28, 6:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tv2rn2/global_rheumatoid) has announced the addition of the "Global Rheumatoid Arthritis Drugs Market 2014-2018" report to their offering. RA is a chronic disease that leads to inflammation and pain in the human body's joints such as wrists, fingers, knees, feet, and ankles. In addition, it causes inflammation of the tissues that surround the joints and in other organs. The symptoms of RA begin slowly, usually just mild pain around the joints coupled with stiffness and fatigue, and in the later stages it causes inflammation of the joints. It can occur at any age, even in children, which is called juvenile arthritis. The disease is three times more common in women than in men. Genetic and environmental elements are known to contribute in the development of RA. The analysts forecast the Global Rheumatoid Arthritis Drugs market will grow at a CAGR of 4.09 percent over the period 2013-2018. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Competitive Assessment of Top Drugs 08. Five Forces Analysis 09. Market Segmentation by Category 10. Geographical Segmentation 11. Buying Criteria 12. Rate of Incidence and Prevalence 13. Pipeline Snapshot 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - AbbVie Inc. - Amgen Inc. - Bristol-Myers Squibb Co. - F. Hoffmann-La Roche Ltd. - Janssen Pharmaceuticals Inc. - Pfizer Inc. - AB Science SA - Astellas Pharma Inc. - AstraZeneca plc - Biogen Idec Inc. - Boehringer Ingelheim GmbH - Celgene Corp. - Daiichi Sankyo Co. Ltd. - Eli Lilly & Co. - GE Healthcare Co. - Genmab A/S - GSK plc - Incyte Corp. - Merck & Co. Inc. - Mitsubishi Tanabe Pharma Corp. - Novartis AG - Novo Nordisk A/S - Rigel Pharmaceuticals Inc. - Sanofi - Takeda Pharmaceutical Co. Ltd. - UCB SA - Vertex Pharmaceuticals Inc. For more information visit http://www.researchandmarkets.com/research/tv...rheumatoid
Second Quarter 2014 Net Sales Figures for Arzerra(r)
GlobeNewswire - Wed Jul 23, 6:11AM CDT
Company Announcement
Genmab Announces Phase III Study of Daratumumab in Front Line Multiple Myeloma
GlobeNewswire - Fri Jul 18, 8:18AM CDT
-- New Phase III study of daratumumab in front line multiple myeloma
Esophageal Cancer Therapeutic Pipeline Review, H1 2014
M2 - Tue Jul 15, 11:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/j6z3g6/esophageal_cancer) has announced the addition of the "Esophageal Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - Amgen Inc. - GlaxoSmithKline plc - Gilead Sciences, Inc. - Daiichi Sankyo Company, Limited - Novartis AG - Ono Pharmaceutical Co., Ltd. - CTI BioPharma Corp. - Genmab A/S - Advaxis, Inc. - Immunomedics, Inc. - Takara Bio Inc. - Synta Pharmaceuticals Corp. - Transgene Biotek Limited - Supratek Pharma Inc. - Glycotope GmbH - Hutchison MediPharma Limited - Advantagene, Inc. - CerRx, Inc. - Cerulean Pharma, Inc. - MacroGenics, Inc. - Merrimack Pharmaceuticals, Inc. - Omnitura Therapeutics Inc. - Omeros Corporation - Oncolys BioPharma Inc. - ImmunoFrontier, Inc. - Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. - Mebiopharm Co., Ltd. - Kite Pharma, Inc For more information visit http://www.researchandmarkets.com/research/j6...eal_cancer
Genmab to Receive Milestone Payment in DuoBody Platform Collaboration with Janssen
GlobeNewswire - Mon Jul 14, 8:59AM CDT
Genmab A/S (OMX:GEN) announced today it has reached a milestone in its DuoBody technology platform collaboration with Janssen Biotech, Inc. ("Janssen"
, triggering a $3 million milestone payment. The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting two inflammatory mediators, proteins which play a key role in major autoimmune diseases. Johnson & Johnson to Make $25M Milestone Payment to Genmab - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 12:10PM CDT
The payment was triggered by progress in an ongoing phase III study on experimental cancer treatment, daratumumab.
Genmab Reaches USD 25 Million Milestone in Daratumumab Collaboration with Janssen
GlobeNewswire - Mon Jul 07, 9:24AM CDT
Company Announcement
GSK and Genmab Receive EU Authorization for Arzerra(tm) (ofatumumab) as First-Line Treatment for Chronic Lymphocytic Leukemia (CLL) in Combination with Chlorambucil or Bendamustine for Patients Ineligible for Fludarabine-based Therapy
GlobeNewswire - Thu Jul 03, 8:39AM CDT
Company Announcement
GSK and Genmab announce top-line results from a Phase III study of ofatumumab versus physicians' choice for bulky fludarabine-refractory CLL
GlobeNewswire - Fri Jun 27, 1:27PM CDT
Company Announcement
Genmab Reaches $22 Million Milestone in Daratumumab Collaboration with Janssen
GlobeNewswire - Wed Mar 26, 5:58PM CDT
Company Announcement
Genmab Announces Phase III Study of Daratumumab in Relapsed or Refractory Multiple Myeloma
GlobeNewswire - Tue Mar 04, 11:48PM CST
Company Announcement
Genmab 2013 Annual Report
GlobeNewswire - Tue Mar 04, 10:23AM CST
Genmab A/S (Copenhagen:GEN) today published its Annual Report for 2013. Below is a summary from the report of business progress and financial performance for the year, and financial outlook for 2014. The full report is attached as a PDF file and can be found on the investor section of the company's website, www.genmab.com.
Arzerra(R) Fourth Quarter and Full Year 2013 Net Sales Figures
GlobeNewswire - Wed Feb 05, 6:15AM CST
Company Announcement
Can Genmab (GNMSF) Run Higher on Strong Earnings Estimate Revisions? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 7:47AM CST
Genmab could be an interesting play for investors because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.
